Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.38 |
| ▸ | ATM | Q13315 | 2/20 | 0.38 |
| ▸ | ATR | Q13535 | 2/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | CDK4 | P11802 | 2/20 | 0.36 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | CCND3 | P30281 | 1/20 | 0.36 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.36 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16132009 | 0.82 | MAP4K4 (0.50) | MAP4K4HRH3HRH4PDE10AEGLN2 | |
| SCHEMBL13279806 | 0.79 | MAP4K4 (0.54) | MAP4K4HRH3HRH4PDE10AEGLN2 | |
| SCHEMBL18081393 | 0.79 | CHRNB2 (0.55) | MAP4K4 | |
| SCHEMBL20038654 | 0.79 | MAP4K4 (0.48) | MAP4K4HRH3HRH4PDE10AEGLN2 | |
| SCHEMBL22006820 | 0.77 | NPC1 (0.50) | HRH3 | |
| SCHEMBL10141626 | 0.76 | MAP4K4 (0.48) | MAP4K4HRH3HRH4ATMATR | |
| SCHEMBL14349211 | 0.76 | MAP4K4 (0.48) | MAP4K4HRH3HRH4ATMATR | |
| SCHEMBL15247305 | 0.76 | MAP4K4 (0.48) | MAP4K4HRH3HRH4ATMATR | |
| SCHEMBL20046660 | 0.76 | LMNA (0.37) | HRH3HRH4 | |
| SCHEMBL20037694 | 0.75 | MAP4K4 (0.44) | MAP4K4HRH3HRH4PDE10AMCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140288044-A1 | COMPOSITIONS AND THERAPEUTIC USES OF IKK-RELATED KINASE EPSILON AND TANKBINDING KINASE 1 INHIBITORS | ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) | 2014-09-25 | — | — | US | disclosed |
| WO-2012142329-A1 | COMPOSITIONS AND THERAPEUTIC USES OF IKK-RELATED KINASE EPSILON AND TANKBINDING KINASE 1 INHIBITORS | MYREXIS, INC. (US) | 2012-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288044-A1 | COMPOSITIONS AND THERAPEUTIC USES OF IKK-RELATED KINASE EPSILON AND TANKBINDING KINASE 1 INHIBITORS | CSNK1G1, PRKCE, PHKG1 | MAP4K4 295/4885HRH3 4523/4885HRH4 4661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.